Early diagnosis of the mucopolysaccharidoses is based on clinical suspicion supported by evidence of abnormal glycosaminoglycan (GAG) excretion in urine and confirmed by appropriate lysosomal enzyme assays. Many laboratories offer one or more of a selection of simple screening tests for excess urinary GAG excretion and some also provide qualitative examination of isolated GAG by electrophoresis or thin layer chromatography. The majority of laboratories in the United Kingdom, having found an abnormal screening result, would refer abnormal samples to one of seven reference laboratories which are also able to offer enzyme assays. There is no national quality assurance scheme for these rare but important diagnostic tests.
We were prompted to initiate a quality assessment exercise for urinary GAG excretion following concern expressed by parents at an annual conference of the Mucopolysaccharide (MPS) Society (a self-help group for parents and families of MPS children) about the delays in investigation and the diagnostic errors which had occurred and were likely to occur in the future. Although enzyme assays for the diagnosis of MPS disease are available at reference centres, examination of urine is still an important initial investigation in the majority of district hospital laboratories.
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METHODS
A letter was published in the Newsletter of the Association of Clinical Biochemists inviting laboratories to participate in a national MPS quality assurance scheme. Initially 15 laboratories showed interest and 33 are currently involved. All were asked to send details of their analytical methods and this information was supplemented later by the circulation of a questionnaire on methods and workload.
A series of random urine samples were collected from six MPS children and two non-MPS children. The samples from each child were pooled and an aliquot distributed to participating laboratories. A sample from a patient with Morquio disease (MPS IV) was split and distributed twice with different clinical information and stated age. The reasons for this will be discussed later.
Samples numbered four and eight were not used in the QC exercise because sample four was found to be infected, and the volume of sample eight was too small for distribution.
Ten millilitre aliquots of the urine were stored without preservatives at -20°C until the time of dispatch. These were then sent by first class postal service to participating laboratories accompanied by limited clinical information (Table  1) . Laboratories were asked to report their results in the form that they would usually use incidence of false positive and false negative results shown in Table 3 illustrates the fact that simple qualitative tests were unreliable. The mean, standard deviation and coefficient of variation were calculated for all grouped quantitative data for each sample (Table 4 ). Data on sample seven represent blind repeat analyses on sample five and show good agreement.
The laboratories using methods to identify the GAG excretion pattern could be divided into those using one-dimensional electrophoresisI alone, those using thin layer chromatography' alone and those using a combination of one of these methods with two-dimensional electrophoresis.' The results from these laboratories are had the sample been referred by one of their clinicians. The time taken to receive the report and the interpretive comments were recorded as well as all qualitative and quantitative test results. A report was sent to each participating laboratory giving the actual diagnosis, the mean result and the standard deviation for all quantitative method data received and a comment from one of us (CP) on the clinical interpretation where appropriate.
RESULTS
Seventeen laboratories (52%) analysed the samples using a qualitative or quantitative screening test alone; whereas the remaining 16 (48%) also provided information on the GAG excretion pattern by electrophoresis or thin layer chromatography. The latter group included seven laboratories offering a regional diagnostic service for MPS and other inherited diseases. Reports were returned on 83% of samples and 85% of questionnaires. Three laboratories failed to return any information and gave no explanation. Technical catastrophy or staff shortages were given as explanation for non-return of results by two laboratories. The average length of time for reports to be returned was 21 days with a range of between 7 and 60 days.
A variety of screening tests were used and 10 laboratories used more than one ( Table 2 ). The summarised in Table 5 . Detection of keratan sulphate was the most frequent problem for those using one-dimensional electrophoresis and extra unidentified GAG bands were frequently reported by laboratories using two-dimensional electrophoresis. although these did not influence diagnosis.
One laboratory reported GAG levels with no reference range and no suggestion as to whether the reported result was normal or abnormal, and four screening laboratories reported abnormal results but failed to suggest any further action that should be taken to obtain a diagnosis.
The most common observation in the ques-tionnaire was that a regular and more frequent distribution of samples would be appreciated. Two participants suggested that a report form should be dispatched with each QC sample in order that results could be returned in a set format.
DISCUSSION
We were surprised at the number of laboratory staff failing to return reports (results from only 124 of the 153 samples dispatched were reported to us), although most of then subsequently explained the situation. In the majority of cases it was due to the fact that they were still unsure of their methods and welcomed our samples as tools for evaluating their problems. The length of time taken to return results (up to 60 days) is also disturbing. Part of the delay may have been due to the samples being regarded as non-urgent, although we had asked participants to treat them in their usual manner. We believe that delays beyond 10 days should be regarded as unacceptable in the screening for MPS disorders. The most common explanation for a long delay was that the test was done in batches and samples thus have to wait. We appreciate that it may sometimes be difficult to issue a detailed report including GAG identification within 10 days of receiving the sample; however, in our own laboratory if the initial screening test is raised we issue an interim report advising the clinician of this fact and saying that a full report will be sent after further investigations have been completed. Where appropriate, a telephone call is made to the clinician, asking for further samples and/or extra clinical information.
The tests used by all laboratories are sufficiently simple to break the 'batch rule' and this is important since a positive result means a request for further samples with additional delays and stress for the family. It may also mean that, in combination with late clinical presentation, additions to the family may be on the way and the opportunity for prenatal diagnosis may be lost. However, we appreciate that performing analyses singly or in small batches may not be cost effective in the use of manpower, and it would seem reasonable to suggest that laboratories performing very few analyses would perhaps be better discouraged from doing them.
It was not surprising to find that filter paper spot tests using toluidine blue" or alcian blue! and qualitative turbidity tests using albumin," CPC,7 or CT ADS produced so many errors. This has been documented in the past, particularly in the diagnosis of Sanfilippo disease (MPS III) and was a major finding of a recent study." The surprise was to find so many laboratories (33%) still using these tests although only one used such a test on its own. Four diagnoses would have been missed if spot tests had been the only screening method employed by three of the laboratories in the survey. We believe these tests should be abandoned; an unsolicited view expressed by most of the reference laboratories.
The quantitative screening tests fared rather better with little to choose between alcian blue" or CPC citrate" tests, both giving about 5% false positive results. This low false positive rate only generates a little extra work and there were no false negative results. (The apparent negative results on the urine from the patient with MPS IV will be discussed later.) These tests have the advantage of simplicity and take both the urine concentration and the patient's age into account, which qualitative tests fail to achieve. Few laboratories measured hexuronic acid" since this test requires prior isolation of GAG from the samples. It also uses a concentrated sulphuric acid reagent which is potentially dangerous and, since other quantitative tests provide an adequate alternative, measurement of hexuronic acid should rarely be required.
The inter-laboratory variability of the two quantitative screening tests is probably acceptable, bearing in mind that results are based on a ratio of the test result to creatinine. However the inter-laboratory variability of the latter appears too high considering that it is such a widely measured analyte and should be improved. The poor performance of urine creatinine assays in this type of quality assurance exercise where results are corrected for creatinine concentration, was also observed by the organisers of the UKEQAS scheme for amino acid screening (personal communication). Unfortunately the number of laboratories reporting creatinine and quantitative GAG concentration separately was insufficient .for us to calculate the coefficient of variation of the CPC citrate and alcian blue methods prior to correction for creatinine.
Attempts to define the GAG excretion pattern exposed some problems. Keratan sulphate (KS) was particularly difficult to identify by onedimensional electrophoresis and no laboratory using this test alone made the correct diagnosis on the urine from the patient with MPS IV, although one did state that the diagnosis could not be excluded and recommended enzyme analysis if the clinician felt that this was justified. Another laboratory failed to detect KS by thin layer chromatography but were using the original method of Lippiello and Mankin? rather than the subsequent solvent modification of Humbel and Charnoles" which makes the identific~tion ofKS much easier. In one laboratory with one of the largest workloads, a mistaken MPS diagnosis based on one-dimensional electrophoresis was made on five out of the seven samples examined, illustrating the fact that laboratory error was not related simply to limited experience because of a low workload.
Laboratories using two-dimensional electrophoresis did rather better but that may be because the majority used more than one method or processed a large annual workload, both of which should help in the interpretation of the two dimensional electrophoretic pattern. One laboratory, for example, turned to thin layer chromatography to confirm KS excretion and others used two-dimensional electrophoresis solely to confirm their findings of heparan sulphate (HS) on one-dimensional electrophoresis. One laboratory found additional fractions not found by others leading to the labelling of MPS III as MPS I or II.
Thin layer chromatography of GAG excreted in MPS III sometimes reveals patterns which may be mistaken for MPS I or II and in other cases the heparan sulphate migrates in a similar position to that of chondroitin sulphate and to the inexperienced eye the pattern may appear normal. These anomalies even occur in patients with the same enzyme defect (our own unpublished observations). We are increasingly unable to recommend it, or one-dimensional electrophoresis as suitable diagnostic tools for laboratories with a limited workload, although a combination of the two may be acceptable. Twodimensional electrophoresis should be the preferred method, but is more complex to do and also requires considerable experience for correct interpretation.
The sample from a patient with MPS IV was distributed twice with two different sets of clinical information. On the second occasion it was sent with the child's correct age and appropriate clinical information only to those laboratories offering a complete examination of urinary excretion pattern. All laboratories returning a report were correct in their diagnosis on this occasion except one where KS was missed by one-dimensional electrophoresis.
On the previous occasion when the sample was sent to all laboratories we specifically gave a lower age in the accompanying information so that a quantitative screening test would appear normal for age. However, the clinical history given was designed to suggest that further investigation might be appropriate. On that occasion three laboratories pursued the matter but failed to find KS and therefore reported the sample as normal. Two laboratories having found a positive screening test (a fortuitous error) proceeded to suggest that the patient had a mucopolysaccharidosis on the basis of the clinical history alone. One suggested MPS II and the other MPS III. We believe this unsolicited diagnostic label, which was not based on laboratory data, to be inappropriate and possibly even dangerous. This is especially true for MPS IV where the early clinical features may be indistinguishable from those of MPS I and a suggestion of a diagnosis from the laboratory might be too readily grasped by the physician and transmitted to the parents. Since the prognosis and treatment of the two conditions are quite different, this could well lead to considerable parental distress and loss of confidence in both physician and laboratory: such an error has been part of our own experience. The results obtained from the splitting of this sample also highlight the importance of relating GAG excretion levels to the patient's age.
Overall we believe this quality assessment exercise to have been worthwhile. Some laboratories have reviewed their methods in the light of their experience. It was gratifying to note that the reference laboratories got a correct diagnosis in all samples examined. None of the reference laboratories would want to handle all the samples screened each year (a total of between 2500 and 3000 by the laboratories in this study alone). However, it would seem appropriate to refer samples to them which included not only those urines found positive by appropriate quantitative screening tests which take age and urine concentration into account, but also other samples where clinical suspicion is high even when the MPS screen is negative. Relatively few of the urine samples sent to the laboratory for 'metabolic screen' would fall into the latter category.
We propose to continue with this quality assurance scheme with more frequent circulation of samples in the hope that there will be continuing improvement in the initial laboratory screening test for the mucopolysaccharidoses. However, practical difficulties in obtaining sufficient urine (350 mL is required for distribution to all laboratories currently involved in the scheme) from patients with MPS, who are often mentally retarded and incontinent, obviously limit the frequency with which we can dispatch samples. We feel that the inclusion of a report form with each urine would defeat the object of laboratories treating those QC samples as if they were routine requests from a clinician and reporting the results in their customary manner. On the whole, results were reported in a clear and concise manner, but there were laboratories whose reports gave inadequate information as to the significance of the result or failed to suggest further investigations that should be made. It is gratifying to find that we have received considerable feedback from this scheme including enquiries from individual laboratories as to how well they are doing and also suggestions as to how the scheme could be improved. We welcome comments from participants and are encouraged to know that they find the scheme worthwhile.
These preliminary experiences lead us to conclude that laboratories should use a recommended quantitative screening test and should have access to a regional referral centre providing complete urinary GAG analysis and appropriate enzyme assays. One-dimensional electrophoresis and thin layer chromatography may be inadequate methods for the diagnosis of the mucopolysaccharidoses in some samples. No laboratory should be using qualitative turbidity or spot tests and too many laboratories have unacceptable delays in analysis and reporting.
